A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts.

Trial Profile

A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Genital warts
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novan Inc
  • Most Recent Events

    • 20 Mar 2017 Status changed from active, no longer recruiting to completed, according to a Novan media release.
    • 02 Mar 2017 According to Novan media release, data will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology.
    • 03 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top